PUBLICATIONS 1. E. Erikçi, M. Gürsel, I. Gursel , Differential Immune Activation Following Encapsulation of Immunostimulatory CpG Oligodeoxynucleotide in Nanoliposomes. Biomaterials.

32(6):1715-23, 2011. 2. FC. Yagci, O. Aslan, M. Gursel, G. Tincer, Y. Ozdamar, K. Karatepe, KC. Akcali, I. Gursel, Mammalian telomeric DNA suppresses endotoxin induced uveitis. J Biol Chem. 285:28806, 2010. 3. M. Gürsel, I. Gursel, HS. Mostowski, DM. Klinman, CXCL16 Influences the Nature and Specificity of CpG-Induced Immune Activation, J. Immunol., 177:1575, 2006. 4.C. Coban, KJ. Ishii, M. Gürsel, DM. Klinman, N. Kumar, Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors, J.Leuko.Biol., 78:647, 2005. 5. H. Shirota, I. Gursel, M. Gürsel, D. M. Klinman, Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock, J. Immunol, 174:4579, 2005. 6. T. Sugiyama, M. Gürsel, F. Takeshita, C. Coban, J. Conover, T. Kaisho, S. Akira, DM. Klinman, CpG RNA: identification of single stranded RNA that stimulates human CD14+CD11c+ monocytes, J. Immunol, 174:2273, 2005. 7. S. Ito, K.J. Ishii, M. Gürsel, H Shirota, A. Ihata, D. M. Klinman, CpG oligodeoxynucleotides enhance neonatal resistance to listeria infection, J. Immunol, 174:777, 2005. 8. H. Shirota, M. Gürsel, D. M. Klinman, Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFNg and IL-12 mediated signaling, J. Immunol,173:5002, 2004. 9. F. Takeshita, I. Gursel, K.J. Ishii, K. Suzuki, M. Gürsel, D. M. Klinman, Signal transduction pathways mediated by the interaction of CpG DNA with toll-like receptor 9, Semin. Immunol., 16:17, 2004. 10. K. J. Ishii, I. Gursel, M. Gürsel, D. M. Klinman, Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides., Curr. Op. Mol. Ther. 6:166, 2004. 11. D. M. Klinman, R.A. Zeuner, H. Yamada, M. Gürsel, D. Currie, I. Gursel, Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N.Y. Acad. Sci. 1002:112, 2003. 12. I. Gursel*, M. Gürsel*, H. Yamada, F. Takeshita, K. J. Ishii, D. M. Klinman, Repetitive elements present in mammalian telomeres suppress CpG DNA induced immune activation, J. Immunol. 171:1393, 2003. 13. D. Verthelyi, M. Gürsel, RT. Kenney, JD. Lifson, S. Liu, J. Mican, DM. Klinman, CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from a Leishmania Infection, J. Immunol, 170:4717, 2003. 14.RA. Zeuner, D. Verthelyi, M. Gürsel, KJ Ishii, and DM Klinman, Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum., 48:1701, 2003. 15. RA. Zeuner, DM. Klinman, G. Illei, CH. Yarboro, KJ. Ishii, M. Gürsel, D. Verthelyi. Response of PBMC from lupus patients to stimulation by CpG oligondeoxynucleotides. Rheumatology. 42:563, 2003. 16. H. Yamada, I. Gursel, F. Takeshita, J. Conover, KJ. Ishii, M. Gürsel, S. Takeshita, and DM. Klinman, Effect of Suppressive DNA on CpG-Induced Immune Activation, J. Immunol, 169:5590, 2002.

17. M. Gürsel, D. Verthelyi, D. M. Klinman, CpG oligodeoxynucleotides stimulate human monocytes to mature into functional dendritic cells Eur. J. Immunol., 32:2617, 2002. 18. M. Gürsel, D. Verthelyi, I. Gursel, KJ. Ishii, DM. Klinman, Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides, J. Leuko. Biol.,71:813, 2002. 19. D.M. Klinman, F. Takeshita, I. Gursel, C. Leifer, K.J. Ishii, D. Verthelyi, M. Gürsel CpG DNA: recognition by and activation of monocytes, Microbes and Infection, 4:897, 2002. 20. KJ. Ishii, F.Takeshita, I. Gursel, M. Gürsel, J. Conover, A. Nussenzweig, DM. Klinman, Potential role of PI3 kinases, rather than DNA-PK, in CpG DNA induced immune activation, J. Exp. Med., 196:269, 2002. 21. F. Takeshita, C. Leifer, İ. Gürsel, M. Gürsel, K. J. Ishii, D. M. Klinman, Cutting Edge: Role of Toll-like receptor-9 in CpG DNA induced activation of human cells. J. Immunol. 167:3555, 2001. 22. İ. Gürsel, M. Gürsel, K. J. Ishii, DM Klinman, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides, J. Immunol., 167:3224, 2001. 23. D. Verthelyi, K.J. Ishii, M. Gürsel, F. Takeshita, D. M. Klinman, Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs., J. Immunol., 166:2372, 2001. 24. DM. Klinman, S. Kampstrup, D. Verthelyi, İ. Gürsel, KJ. Ishii, F. Takeshita, M. Gürsel, Activation of the innate immune system by CpG:Therapeutic applications and safety issues. Springer Semin. Immunopathol., 2: 173, 2000. 25. D. M. Klinman, K. J. Ishii, M. Gürsel, İ. Gürsel, S. Takeshita and F. Takeshita, Immunotherapeutic applications of CpG containing oligodeoxynucleotides, Drug News and Perspectives 13:289, 2000. 26. M. Gürsel, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G, Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 17:1376,1999. 27. M. Gürsel , G. Gregoriadis, The immunological co-adjuvant action of liposomal interleukin-2: The role of mode of localization of the cytokine and antigen in the vesicles. J. Drug Target., 5: 93, 1997. 28. M. Gürsel and G. Gregoriadis, Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. Immunol. Lett., 55(3), 161-165, 1997. 29. M. Gürsel and G. Gregoriadis, The Immunological co-adjuvant action of liposomal Interleukin-15, In: Vaccine Design: The role of Cytokine Networks, Eds. G. Gregoriadis, A.C. Allison, and B. Mc.Cormack, Plenum Publishing Corporation, New York, 175-180 (1997). 30. G. Gregoriadis, İ. Gürsel, M. Gürsel and B. Mc.Cormack, Liposomes as immunological adjuvants and vaccine carriers. J. Contr. Rel., 41, 49-56, 1996. 31.T. Yoshioka, N. Skalko, M. Gürsel, G. Gregoriadis, A. T. Florence, A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system:Potential uses in drug and vaccine deliveryJ. Drug Target.2:533,1995. 32. M. Gürsel and V. Hasırcı, Influence of membrane components on the stability and drug release properties of REVs: Light sensitive all-trans retinal, negatively charged phospholipid dicetylphosphate and cholesterol., J. Microencapsulation, 12(6):661-669 (1995).

33. M. Gürsel and G. Gregoriadis, Interleukin-2 as a co-adjuvant for liposomal tetanus toxoid., in: Vaccines: New Generation Immunological Adjuvants., Eds. G. Gregoriadis, A.C. Allison, G. Poste and B. Mc.Cormack, Plenum Publishing Corporation, New York, 45-50 (1995). 34. M. Gürsel and G. Gregoriadis, Immunoadjuvant action of liposomes containing interleukin-2 as a co-adjuvant, ‘International Symposium on Controlled Release of Bioactive Materials’, 22:572-573 (1995).